| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| Lung CSC (Cancer Stem Cells) markers (CD133, CD44, ALDHA1, Nanog and Oct4) |
| 4411- | AgNPs, | Eco-friendly synthesis of silver nanoparticles using Anemone coronaria bulb extract and their potent anticancer and antibacterial activities |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 4376- | AgNPs, | Interaction of multi-functional silver nanoparticles with living cells |
| - | in-vitro, | Nor, | L929 | - | in-vitro, | Lung, | A549 |
| 4555- | AgNPs, | Silver nanoparticles from Dendropanax morbifera Léveille inhibit cell migration, induce apoptosis, and increase generation of reactive oxygen species in A549 lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
| 5147- | AgNPs, | Size dependent anti-invasiveness of silver nanoparticles in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 1559- | Api, | Dually Active Apigenin-Loaded Nanostructured Lipid Carriers for Cancer Treatment |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 5880- | CAR, | In vitro and in vivo antitumor potential of carvacrol nanoemulsion against human lung adenocarcinoma A549 cells via mitochondrial mediated apoptosis |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | PC9 |
| 1574- | Citrate, | Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Melanoma, | WM983B | - | in-vivo, | NA, | NA |
| 1602- | Cu, | A simultaneously GSH-depleted bimetallic Cu(ii) complex for enhanced chemodynamic cancer therapy† |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
| 2304- | CUR, | Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 1979- | CUR, | Rad, | Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase |
| - | in-vitro, | Lung, | A549 |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1904- | GoldNP, | AgNPs, | Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis |
| - | in-vitro, | Lung, | H157 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Colon, | HCT15 | - | in-vitro, | Melanoma, | A375 |
| 2875- | HNK, | Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | SCC, | H226 |
| 2879- | HNK, | Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function |
| - | in-vitro, | Lung, | H226 | - | in-vivo, | NA, | NA |
| 2892- | HNK, | Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H385 | - | in-vitro, | Nor, | BEAS-2B |
| 2895- | HNK, | Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity |
| - | in-vitro, | Lung, | PC9 |
| 1781- | MEL, | Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial |
| - | Trial, | Lung, | NA |
| 5796- | MET, | Tumor, whole blood, plasma, and tissue concentrations of metformin in lung cancer patients |
| - | Human, | Lung, | NA |
| 2261- | MF, | Tumor-specific inhibition with magnetic field |
| - | in-vitro, | Nor, | GP-293 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 |
| 507- | MF, | Effects of extremely low frequency electromagnetic fields on the tumor cell inhibition and the possible mechanism |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | GP-293 |
| 186- | MFrot, | MF, | Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Lung, | NA |
| 1812- | Oxy, | Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NA | - | in-vitro, | NA, | BEAS-2B |
| 1670- | PBG, | Lung response to propolis treatment during experimentally induced lung adenocarcinoma |
| - | in-vivo, | Lung, | NA |
| 1950- | PL, | Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 |
| 1953- | PL, | Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | WI38 |
| 3011- | RosA, | Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition |
| - | in-vitro, | GBM, | SH-SY5Y | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | MCF10 |
| 4480- | SeNPs, | Chit, | Biogenic synthesized selenium nanoparticles combined chitosan nanoparticles controlled lung cancer growth via ROS generation and mitochondrial damage pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HK-2 |
| 2010- | SK, | Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway |
| - | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | H1650 | - | in-vitro, | Nor, | CCD19 |
| 2185- | SK, | Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis |
| - | in-vitro, | Lung, | LLC1 | - | in-vitro, | Melanoma, | B16-BL6 | - | in-vivo, | NA, | NA |
| 2110- | TQ, | Nigella sativa seed oil suppresses cell proliferation and induces ROS dependent mitochondrial apoptosis through p53 pathway in hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
| 3109- | VitC, | Vitamin C Inhibited Pulmonary Metastasis through Activating Nrf2/HO-1 Pathway |
| - | in-vitro, | Lung, | H1299 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:15 Cells:% prod#:% Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid